Get the Stockscreener App
4.645
1.20%
0.055
Galectin Therapeutics Inc stock is traded at $4.645, with a volume of 207.89K.
It is up +1.20% in the last 24 hours and up +19.10% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$4.59
Open:
$4.57
24h Volume:
207.89K
Relative Volume:
0.31
Market Cap:
$296.43M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-6.363
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
-21.80%
1M Performance:
+19.10%
6M Performance:
+193.99%
1Y Performance:
+71.40%
1-Day Range:
$4.45
$4.7089
1-Week Range:
$4.21
$6.55
52-Week Range:
$0.726
$6.55
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.6273 | 294.04M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
597.07 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.07 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.15 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.62 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Key metrics from Galectin Therapeutics Inc.’s quarterly dataPortfolio Value Summary & Weekly Setup with High ROI Potential - newser.com
IPO Launch: Can Galectin Therapeutics Inc reach all time highs this yearMarket Performance Summary & Expert Verified Movement Alerts - خودرو بانک
Analyst Calls: Whats next for Galectin Therapeutics Inc stockMarket Risk Analysis & Risk Managed Investment Strategies - خودرو بانک
Tools to assess Galectin Therapeutics Inc.’s risk profileVolume Spike & Daily Growth Stock Tips - newser.com
Published on: 2025-09-17 20:08:02 - newser.com
Published on: 2025-09-17 12:49:30 - newser.com
Fund Flows: Will Galectin Therapeutics Inc outperform its industry peers2025 Top Gainers & Expert-Curated Trade Recommendations - خودرو بانک
Market Leaders: Will Citius Oncology Inc benefit from sector rotationJuly 2025 Big Picture & Free AI Powered Buy and Sell Recommendations - خودرو بانک
Aug Rallies: Does Galectin Therapeutics Inc have a sustainable dividend2025 Valuation Update & Long Hold Capital Preservation Plans - خودرو بانک
Galectin Therapeutics Inc. stock prediction for this weekPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Will Galectin Therapeutics Inc. continue its uptrendRisk Management & Reliable Volume Spike Trade Alerts - newser.com
Market reaction to Galectin Therapeutics Inc.’s recent newsEntry Point & Stepwise Trade Signal Implementation - newser.com
How sentiment analysis helps forecast Galectin Therapeutics Inc.Buy Signal & Safe Capital Investment Plans - newser.com
Aug Highlights: Does Galectin Therapeutics Inc have consistent dividend growthWall Street Watch & Technical Buy Zone Confirmation - خودرو بانک
Galectin Therapeutics (NASDAQ:GALT) CFO Jack W. Callicutt Sells 8,706 Shares - MarketBeat
Joel Lewis Sells 14,000 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Income Plays: Will Galectin Therapeutics Inc outperform its industry peersMarket Risk Report & Free Safe Capital Growth Stock Tips - خودرو بانک
Does Galectin Therapeutics Inc have consistent dividend growthEarnings Beat & Consistent Income Trade Ideas - خودرو بانک
Technical signs of recovery in Galectin Therapeutics Inc.July 2025 Update & Expert Curated Trade Ideas - newser.com
Volatility Watch: What is the long term forecast for Galectin Therapeutics Inc stock2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Galectin therapeutics CFO sells shares for $56,053 - Investing.com India
Galectin therapeutics CFO sells shares for $56,053 By Investing.com - Investing.com Nigeria
Bond Watch: Can Galectin Therapeutics Inc weather a recessionInsider Selling & Long-Term Safe Investment Ideas - خودرو بانک
Breakout Move: Will Galectin Therapeutics Inc. face regulatory challengesTake Profit & Weekly Watchlist for Hot Stocks - خودرو بانک
Quarterly Risk: Will The E.W. Scripps Company outperform the market in YEARMarket Sentiment Report & Consistent Profit Trading Strategies - خودرو بانک
Galectin Therapeutics Inc. $GALT Shares Bought by Geneos Wealth Management Inc. - Defense World
Published on: 2025-09-14 19:23:29 - newser.com
Analyzing Galectin Therapeutics Inc. with risk reward ratio chartsTake Profit & Growth Focused Stock Pick Reports - newser.com
Insider Trading At Galectin Therapeutics Inc (NASDAQ: GALT): What Did We Note? - stocksregister.com
How to integrate Galectin Therapeutics Inc. into portfolio analysis toolsMarket Risk Summary & Entry Point Strategy Guides - newser.com
Has Galectin Therapeutics Inc. found a price floorJuly 2025 Trends & Low Risk Profit Maximizing Plans - newser.com
Tick level data insight on Galectin Therapeutics Inc. volatilityJobs Report & Free Fast Entry Momentum Trade Alerts - newser.com
Is Galectin Therapeutics Inc. stock entering bullish territory2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
What Fibonacci levels say about Galectin Therapeutics Inc. reboundMarket Weekly Review & Step-by-Step Trade Execution Guides - Newser
Galectin Therapeutics Inc. (NASDAQ:GALT) Surges 27%; Individual Investors Who Own 53% Shares Profited Along With Insiders - 富途牛牛
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know - sharewise.com
Will Galectin Therapeutics Inc. stock recover after recent dropRate Hike & Safe Entry Point Alerts - Newser
What technical models suggest about Galectin Therapeutics Inc.’s comebackTrade Signal Summary & Expert Approved Momentum Ideas - Newser
Is Galectin Therapeutics Inc. building a consolidation baseMarket Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Chart based analysis of Galectin Therapeutics Inc. trendsQuarterly Trade Review & Long-Term Growth Portfolio Plans - Newser
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CALLICUTT JACK W | Chief Financial Officer |
Sep 12 '25 |
Sale |
6.44 |
8,706 |
56,054 |
7,614 |
| LEWIS JOEL | President and CEO |
Sep 12 '25 |
Option Exercise |
2.39 |
14,000 |
33,460 |
846,592 |
| LEWIS JOEL | President and CEO |
Sep 12 '25 |
Sale |
6.36 |
14,000 |
89,048 |
832,592 |
0.15%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):